- Previous Close
15.52 - Open
15.44 - Bid 15.97 x 100
- Ask 16.23 x 100
- Day's Range
15.18 - 16.32 - 52 Week Range
12.78 - 24.00 - Volume
110,605 - Avg. Volume
77,706 - Market Cap (intraday)
180.816M - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-3.03 - Earnings Date May 27, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.00
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
www.mediwound.comRecent News: MDWD
View More
Performance Overview: MDWD
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDWD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDWD
View MoreValuation Measures
Market Cap
174.85M
Enterprise Value
172.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.65
Price/Book (mrq)
5.61
Enterprise Value/Revenue
8.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-149.46%
Return on Assets (ttm)
-17.33%
Return on Equity (ttm)
-96.33%
Revenue (ttm)
20.22M
Net Income Avi to Common (ttm)
-30.22M
Diluted EPS (ttm)
-3.03
Balance Sheet and Cash Flow
Total Cash (mrq)
43.16M
Total Debt/Equity (mrq)
22.25%
Levered Free Cash Flow (ttm)
-6.59M